



For immediate release

03 Feb 2012

Zilico presenting at the ASCCP, San Francisco

Mr John Tidy, Consultant Gynaecological Oncologist at the Royal Hallamshire Hospital Sheffield and founder of Zilico, will be presenting the results from the pivotal EU multi-centre study at the 2012 Biennial ASCCP scientific meeting. His presentation is entitled - "IMPROVED COLPOSCOPIC PERFORMANCE USING ELECTRICAL IMPEDANCE SPECTROSCOPY (APX100) AS AN ADJUNCT".

In addition, Zilico will disseminate the trial results through its international network of Key Opinion Leaders (KOLs).

For more information please contact: Sameer Kothari, CEO, Zilico Ltd, tel: 0114 222 4580; email: sameer.kothari@zilico.co.uk

Notes for editors:

Zilico Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two product applications are under development: the first for the referral market and the second for the screening market. Clinical data on 1000 women has demonstrated superior performance over existing diagnostic procedures.

Zilico has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal, pre cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Zilico's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Zilico has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Zilico product applications consist of a handheld device and a base unit together with a single-use disposable sleeve for each test.

The European multi-centre trial is designed to demonstrate the performance of its portable diagnostic device within a cervical cancer screening programme. The device is positioned as an adjunct to colposcopy to help accurately identify sites for biopsy. The trial has been carried out at three centres with international reputations in colposcopy and cervical cancer. A total of over 400 women were recruited into the trial. Zilico is disseminating the results and will use the data from this trial to obtain a CE Mark for the use of the device as an adjunct to colposcopy and expects to launch the product by the end of 2012.

The 2012 Biennial ASCCP scientific meeting is being held in San Francisco on 14 – 17 March. More details about the ASCCP can be found at <http://www.asccp.org/Home/tabid/5809/Default.aspx>